Clinical Trial Update: αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating αDC1 vaccine with a chemokine modulatory regimen as adjuvant therapy for peritoneal surface malignancies, completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface
• Malignant Peritoneal Mesothelioma
• Peritoneal Carcinomatosis

Drugs mentioned

• Chemokine Modulatory Regimen (CKM) (chemokine modulatory regimen)
• αDC1 vaccine (alpha dendritic cell vaccine)

Snippet

Sponsor: David Bartlett | Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-01-28